HK1071079A1 - Use of soluble fgl2 as an immunosuppressant - Google Patents

Use of soluble fgl2 as an immunosuppressant

Info

Publication number
HK1071079A1
HK1071079A1 HK05104187.0A HK05104187A HK1071079A1 HK 1071079 A1 HK1071079 A1 HK 1071079A1 HK 05104187 A HK05104187 A HK 05104187A HK 1071079 A1 HK1071079 A1 HK 1071079A1
Authority
HK
Hong Kong
Prior art keywords
soluble fgl2
methods
immunosuppressant
soluble
fgl2 protein
Prior art date
Application number
HK05104187.0A
Other languages
English (en)
Inventor
Gary Levy
Original Assignee
Veritas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veritas Therapeutics Inc filed Critical Veritas Therapeutics Inc
Publication of HK1071079A1 publication Critical patent/HK1071079A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HK05104187.0A 2002-03-01 2005-05-19 Use of soluble fgl2 as an immunosuppressant HK1071079A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36105602P 2002-03-01 2002-03-01
PCT/CA2003/000273 WO2003074068A2 (fr) 2002-03-01 2003-02-28 Utilisation de fgl2 soluble en tant qu'immunosuppresseur

Publications (1)

Publication Number Publication Date
HK1071079A1 true HK1071079A1 (en) 2005-07-08

Family

ID=27789065

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104187.0A HK1071079A1 (en) 2002-03-01 2005-05-19 Use of soluble fgl2 as an immunosuppressant

Country Status (8)

Country Link
US (2) US7632495B2 (fr)
EP (1) EP1482961B1 (fr)
AT (1) ATE433326T1 (fr)
AU (1) AU2003208197A1 (fr)
CA (1) CA2477312C (fr)
DE (1) DE60327925D1 (fr)
HK (1) HK1071079A1 (fr)
WO (1) WO2003074068A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
CA2682429A1 (fr) * 2009-05-20 2010-11-20 Gary Levy Epreuve permettant de mesurer les niveaux de fgl-2 dans le plasma, et ses procedes et utilisations
WO2014067993A1 (fr) * 2012-11-01 2014-05-08 Veterinærinstituttet Nouvelles protéines hybrides pour le traitement de maladies allergiques
US9005630B2 (en) * 2012-11-01 2015-04-14 Veterinaerinstituttet Fusion proteins for the treatment of allergic diseases
WO2015143343A2 (fr) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique
WO2021199046A1 (fr) * 2020-03-31 2021-10-07 Biond Biologics Ltd. Compositions immunomodulatrices et leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE69835949D1 (de) * 1997-05-15 2006-11-02 Trillium Therapeutics Inc Verfahren um immunkoagulation zu modulieren
US20060078550A1 (en) * 2002-02-07 2006-04-13 Gary Levy Porcine fgl2

Also Published As

Publication number Publication date
US20100048486A1 (en) 2010-02-25
EP1482961A2 (fr) 2004-12-08
WO2003074068A3 (fr) 2003-12-18
AU2003208197A8 (en) 2003-09-16
EP1482961B1 (fr) 2009-06-10
WO2003074068A2 (fr) 2003-09-12
CA2477312A1 (fr) 2003-09-12
ATE433326T1 (de) 2009-06-15
US20050164923A1 (en) 2005-07-28
CA2477312C (fr) 2013-02-26
DE60327925D1 (de) 2009-07-23
US7632495B2 (en) 2009-12-15
AU2003208197A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
HK1030625A1 (en) Methods and compositions for immunomodulation
WO2004047728A3 (fr) Compositions et procedes destines au traitement de maladies de nature immune
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
EA200602137A1 (ru) Гидрогелевые препараты интерферона
EP1575480A4 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
EP1576137A4 (fr) Compositions et methodes de traitement de maladies liees au systeme immunitaire
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2001068697A3 (fr) Techniques et compositions relatifs à l'immunorégulation
MXPA02012249A (es) Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia.
AU2003236156A1 (en) Pharmaceutical compositions used for immune disease treatment and improvement
WO2003102162A3 (fr) Nouvelles cellules dendritiques tolerogeniques et utilisations therapeutiques de celles-ci
WO2005009366A3 (fr) Restauration d'une fonction vasculaire
WO2004081199A3 (fr) Nouvelles compositions et methodes de traitement de troubles du systeme immunitaire
WO2005123113A3 (fr) Compositions d'interferons et leurs methodes d'utilisation
WO2004030631A3 (fr) Compositions anticancereuses et contre les maladies infectieuses, et procedes d'utilisation correspondants
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
AU8349301A (en) Dna vaccines encoding hiv accessory proteins
WO2006079121A3 (fr) Methodes destinees au traitement d'une maladie, dans lesquelles est utilise un interferon glycosyle
WO2005011728A3 (fr) Utilisation de cd164 soluble pour les troubles inflammatoires ou auto-immuns
WO2004004649A3 (fr) Compositions et procedes destines au traitement de maladies liees au systeme immunitaire
EP1498145A4 (fr) Leurre destine au traitement et/ou a la prevention d'une maladie allergique associee a la cytokine th2, proteine mutante gata3 et compositions medicinales contenant celle-ci
WO2004024069A3 (fr) Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
UA81613C2 (ru) Стимуляция тимозином генетической иммунизации
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130228